Co-Trimoxazole 480 mg (Sulfamethoxazole/Trimethoprim)
Price range: 44.00$ through 75.00$
Product Overview
Co‑Trimoxazole 480 mg, manufactured by Omega Pharma, is a fixed‑dose combination antibiotic that unites sulfamethoxazole and trimethoprim in a single tablet strength of 480 mg. The product is presented in blister strips containin
| Active Ingredients | Sulfamethoxazole/Trimethoprim |
|---|---|
| Delivery Time | 6 To 15 days |
| Indication | Bacterial Infections |
| Manufacturer | Omega Pharma |
| Packaging | 10 tablets in 1 strip |
| Strength | 480mg |
| Pack Size | Price | Quantity | |
|---|---|---|---|
| 50 Tablet/s | 44.00$ | ||
| 100 Tablet/s | 58.75$ | ||
| 200 Tablet/s | 75.00$ |
Product Overview
Co‑Trimoxazole 480 mg, manufactured by Omega Pharma, is a fixed‑dose combination antibiotic that unites sulfamethoxazole and trimethoprim in a single tablet strength of 480 mg. The product is presented in blister strips containing ten tablets, and bulk pack options of one hundred, two hundred, or five hundred tablets are available for patients who require ongoing therapy. Each tablet is film‑coated for ease of swallowing and should be taken with a full glass of water to optimize absorption. The medication is indicated for the treatment of a variety of bacterial infections and is supplied with clear dosing instructions to support safe use.
What is Co‑Trimoxazole?
Co‑Trimoxazole belongs to the sulfonamide class of antimicrobial agents and is formulated as a fixed‑dose combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole functions as a structural analogue of para‑aminobenzoic acid and competitively inhibits the enzyme dihydropteroate synthase, while trimethoprim blocks dihydrofolate reductase, two consecutive steps in the folic acid synthesis pathway that are essential for bacterial growth. This synergistic inhibition creates a bactericidal effect that is active against many Gram‑positive and Gram‑negative organisms. Because the drug targets two distinct enzymatic pathways, the likelihood of resistance development is reduced when the agent is used appropriately. Co‑Trimoxazole is available only by prescription in most countries, and its use should be supervised by a qualified healthcare professional.
Uses and Benefits
The primary therapeutic indication for Co‑Trimoxazole 480 mg is the management of uncomplicated and complicated bacterial infections that are susceptible to this agent. Common clinical applications include community‑acquired respiratory tract infections such as acute bronchitis and pneumonia, urinary tract infections, and select skin and soft‑tissue infections. In dermatology, the drug is sometimes prescribed for moderate to severe acne vulgaris when topical therapy alone does not provide adequate control, leveraging its anti‑inflammatory and antibacterial properties to reduce lesion count over several weeks of treatment. Additionally, Co‑Trimoxazole is used for antimicrobial prophylaxis in certain immunocompromised patient populations, such as individuals undergoing chemotherapy or organ transplantation, where the risk of opportunistic infections is elevated. The medication’s broad spectrum, oral bioavailability, and convenient dosing schedule make it a valuable option in outpatient settings.
How It Works
Co‑Trimoxazole exerts its antimicrobial activity by simultaneously interfering with two consecutive enzymes in the folic acid biosynthetic pathway. Sulfamethoxazole competes with para‑aminobenzoic acid for binding to dihydropteroate synthase, preventing the incorporation of this molecule into dihydropteroic acid. Trimethoprim then binds to dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate, a cofactor required for nucleotide synthesis. The combined blockade leads to a rapid depletion of tetrahydrofolate, which ultimately halts DNA and RNA production and results in bacterial cell death. This dual‑mechanism approach not only enhances potency against a wide range of pathogens but also diminishes the propensity for resistance development compared with agents that target a single pathway.
Dosage Guidelines
Dosage of Co‑Trimoxazole must be individualized based on the patient’s age, body weight, severity of infection, and renal function. For most adult patients the recommended regimen consists of one 480 mg tablet taken twice daily, usually at an interval of twelve hours, to maintain therapeutic drug levels. Pediatric dosing is generally calculated at 6 mg of sulfamethoxazole per kilogram of body weight per day, divided into two doses; this translates to a fraction of the adult tablet depending on the child’s weight. Patients with impaired renal function may require dose reduction, as the drug and its metabolites are primarily eliminated unchanged by the kidneys; in such cases a reduced dose or extended dosing interval is advised to avoid accumulation and potential toxicity. The tablets should be swallowed whole with water and may be taken with food to lessen gastrointestinal discomfort. It is essential to complete the entire prescribed course, even if symptoms improve early, to ensure eradication of the infection and to minimize the risk of developing antimicrobial resistance. Proper storage at room temperature away from moisture and heat is recommended to preserve tablet integrity.
Side Effects
Like all pharmaceutical products, Co‑Trimoxazole can be associated with adverse reactions ranging from mild to severe. The most commonly reported side effects include gastrointestinal disturbances such as nausea, vomiting, abdominal cramping, and diarrhea, as well as dermatologic reactions like pruritus, rash, or mild skin eruptions. Rare but clinically significant events include hematologic abnormalities such as neutropenia, thrombocytopenia, or hemolytic anemia, particularly in patients with pre‑existing blood disorders, and hepatic dysfunction manifested by elevated transaminases or bilirubin. In very rare circumstances, patients may develop severe hypersensitivity reactions, including Stevens‑Johnson syndrome or toxic epidermal necrolysis, which require immediate discontinuation of the drug and urgent medical attention. Patients should be instructed to seek medical care promptly if they experience high fever, painful skin lesions, or any signs of an allergic response. Routine laboratory monitoring of blood counts and liver enzymes is recommended for individuals with underlying liver or kidney disease to detect early evidence of organ dysfunction.
Warnings and Precautions
Co‑Trimoxazole is contraindicated in patients with a known hypersensitivity to sulfonamide derivatives or any inactive ingredients present in the formulation. It should be avoided in pregnant women during the first trimester unless the expected benefit outweighs the potential risk, and it is generally not recommended near term because of the possibility of neonatal kernicterus. The drug is also contraindicated in individuals with severe hepatic impairment or certain enzymatic deficiencies such as glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, which can precipitate hemolytic anemia. Co‑Trimoxazole may interact with several other medications, including warfarin, phenytoin, methotrexate, and certain sulfonylureas, potentially increasing the risk of bleeding, neurotoxicity, or other adverse effects; therefore, a thorough medication review is essential before initiation. Patients should maintain adequate hydration throughout therapy to facilitate renal excretion of the drug and its metabolites. Finally, prescribers should assess renal function prior to dosing and monitor renal parameters periodically during treatment, especially in elderly patients or those with comorbidities that affect kidney function.
Frequently Asked Questions
- Can Co‑Trimoxazole be used for viral infections? No. This medication is active only against susceptible bacteria and has no antiviral activity; using it for viral illnesses can contribute to antimicrobial resistance and is not recommended.
- How long does it take to see improvement in symptoms? Most patients report clinical improvement within 48 to 72 hours after starting therapy, although the full duration of treatment may extend from five to fourteen days depending on the nature and severity of the infection.
- Is it safe to take Co‑Trimoxazole with oral contraceptives? Current evidence does not indicate a significant drug‑drug interaction, but patients should always discuss all concomitant medications, including hormonal contraceptives, with their prescribing clinician.
- What should I do if I miss a dose? If a dose is missed, it should be taken as soon as the patient remembers, provided that it is not close to the time for the next scheduled dose; otherwise, the missed dose should be skipped and the regular dosing schedule resumed to avoid overdose.
- Can the medication be taken with alcohol? There is no direct contraindication against alcohol consumption, but alcohol may exacerbate certain side effects such as dizziness or nausea; therefore, moderation is advised, and patients should be aware of their individual tolerance.
For detailed prescribing information, refer to the U.S. Food and Drug Administration drug label, and for comprehensive patient education see the MedlinePlus resource. Additional scientific background can be found at the National Institutes of Health and on the Wikipedia page for sulfamethoxazole/trimethoprim.
.product-overview, .what-is-product, .uses-benefits, .how-it-works, .dosage, .side-effects, .warnings, .faqs {margin-bottom: 1.5em;}
h2 {color:#2c3e50; border-bottom:1px solid #ddd; padding-bottom:0.3em;}
ol li {margin-left:1.2em;}
Related Products
- Dalacin C (Clindamycin)
- Dalacin C 150 mg (Clindamycin)
- Dalacin C 300 mg (Clindamycin)
- Claribid 250 mg (Clarithromycin)
- Claribid (Clarithromycin)
- Oframax (Ceftriaxone)
- Phexin (Cephalexin)
- Claribid 500 mg (Clarithromycin)
- Oframax 500mg Injection (Ceftriaxone)
- Oframax 1gm Injection (Ceftriaxone)
- Phexin 250 mg (Cephalexin)
- Phexin 500 mg (Cephalexin)
Reviews
There are no reviews yet.